REGISTER FOR THIS EVENT
A new chapter in ATTR-CM: What comes next in clinical practice?
Tuesday 27th January 2026, 13:00 - 13:45 GMT | To be held virtually
For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam® Pharmaceuticals.
Please note that some of the sessions will include data specific to products from Alnylam Pharmaceuticals.
AMVUTTRA® is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients and cardiomyopathy (ATTR-CM).
AMVUTTRA® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
AMVUTTRA® is recommended by NICE as an option for the treatment of hATTR in adults with stages 1 or 2 PN (TA868), and is currently under review by NICE for the treatment of ATTR-CM (ID6470).
A new chapter in ATTR-CM: What comes next in clinical practice?
Dr Carol Whelan, Consultant Cardiologist and Clinical Lead for Heart Failure,
National Amyloidosis Centre, London.
Please see below for the agenda topics.
Evolving patient profiles in ATTR-CM: Are we ready to rethink management? (15 min)
At the heart of ATTR-CM: Redefining first-line therapy in contemporary care (15 min)
Q&A
Register for this event below:
If you have already registered, please join below:
To report an adverse event in the UK:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com